![Cynthe Sims](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Cynthe Sims
Direttore/Membro del Consiglio presso
Artemis Dna, Inc.
Profilo
Cynthe Sims currently works as a Director at Artemis Dna, Inc.
Posizioni attive di Cynthe Sims
| Società | Posizione | Inizio |
|---|---|---|
Artemis Dna, Inc.
 Artemis Dna, Inc. Artemis DNA is a full-service clinical diagnostic laboratory that specializes in precision medicine. The company is certified by the Clinical Laboratory Improvement Amendments (Clia) and accredited by the College of American Pathologists (CAP). The company offers a range of cutting-edge technologies and analytics to improve health through early detection, diagnosis, and management of diseases. The company's oncology portfolio includes a Cancer Risk Profile Panel, Trucheck Pragma Cancer Early Detection Panel, Cancertrack Cancer Monitor and Manage Recurrence Panel, and Cancer Tumor Profiling Panel, which use next-generation sequencing (NGS) and liquid biopsy tests to assess a person's increased risk of developing the disease based on their genetic makeup. The company is based in Irvine, CA. The company was founded in 2019 by Emylee Thai. Emylee Thai has been the CEO since 2019. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Artemis Dna, Inc.
Artemis Dna, Inc. Artemis DNA is a full-service clinical diagnostic laboratory that specializes in precision medicine. The company is certified by the Clinical Laboratory Improvement Amendments (Clia) and accredited by the College of American Pathologists (CAP). The company offers a range of cutting-edge technologies and analytics to improve health through early detection, diagnosis, and management of diseases. The company's oncology portfolio includes a Cancer Risk Profile Panel, Trucheck Pragma Cancer Early Detection Panel, Cancertrack Cancer Monitor and Manage Recurrence Panel, and Cancer Tumor Profiling Panel, which use next-generation sequencing (NGS) and liquid biopsy tests to assess a person's increased risk of developing the disease based on their genetic makeup. The company is based in Irvine, CA. The company was founded in 2019 by Emylee Thai. Emylee Thai has been the CEO since 2019. |
